SAG Hydrochloride

Catalog No.S7779 Batch:S777903

Print

Technical Data

Formula

C28H29Cl2N3OS
Molecular Weight 526.52 CAS No. 2095432-58-7
Solubility (25°C)* In vitro DMSO 82 mg/mL (155.73 mM)
Water 50 mg/mL (94.96 mM)
Ethanol 27 mg/mL (51.28 mM)
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SAG (Smoothened Agonist) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.
Targets
Smoothened [1]
(mouse cultured cell assay)
3 nM(EC50)
In vitro

SAG regulates Smo activity by binding directly to the Smo heptahelical bundle. [1]

SAG induces Smo-dependent signaling through Gli in a GRK2-dependent way. [2]

SAG also (1 nM) induces proliferation of neuronal and glial precursors without affecting the differentiation pattern of newly produced cells. [3]
In vivo

In the adult rat hippocampus, the intracerebroventricular administration of SAG (2.5 nM) significantly increases the number of newly generated cells and extends survival of hippocampal cells. [3]

In mice, SAG (20 μg/g, i.p.) effectively prevents GC-induced neonatal cerebellar developmental abnormalities. [4]

Protocol (from reference)

Kinase Assay:

[1]
  • Cell-Based Assays for Hh Pathway Activation

    Assays for Hh pathway activation in Shh-LIGHT2 cells, a clonal NIH 3T3 cell line stably incorporating Gli-dependent firefly luciferase and constitutive Renilla luciferase reporters, are conducted. For studies of SAG (a chlorobenzothiophene-containing Hh pathway agonist) and PA-SAG, Shh-LIGHT2 cells are cultured to confluency in 96-well plates and then treated with various concentrations of these compounds in DMEM containing 0.5% (vol/vol) bovine calf serum.
Cell Assay:

[1]
  • Cell lines

    Shh-LIGHT2 cells

  • Concentrations

    3 nM

  • Incubation Time

    30 h

  • Method

    Cells were treated with various concentrations of SAG in DMEM containing 0.5% (vol/vol) bovine calf serum.
Animal Study:

[3]
  • Animal Models

    Rat

  • Dosages

    2.5 nM

  • Administration

    Intracerebroventricular administration

References

  • https://pubmed.ncbi.nlm.nih.gov/12391318/
  • https://pubmed.ncbi.nlm.nih.gov/16908539/
  • https://pubmed.ncbi.nlm.nih.gov/20600593/
  • https://pubmed.ncbi.nlm.nih.gov/22013124/

Customer Product Validation

Activating Shh signaling by SAG injection in naïve mice significantly increased BDNF expression, and pretreatment with cyclopamine effectively prevented the upregulation of BDNF induced by SAG (E). Tissues were collected at 2 hours after SAG injection. Six mice were included in each group.

Data from [ , , J Pain Res, 2018, 11:649-659 ]

Selleck's SAG Hydrochloride Has Been Cited by 91 Publications

Identification of functional non-coding variants associated with orofacial cleft [ Nat Commun, 2025, 16(1):6545] PubMed: 40670354
The O-glycosyltransferase C1GALT1 promotes EWSR1::FLI1 expression and is a therapeutic target for Ewing sarcoma [ Nat Commun, 2025, 16(1):1267] PubMed: 39894896
FAK signaling suppression by OCT4-ITGA6 mediates the effectively removal of residual pluripotent stem cells and enhances application safety [ Theranostics, 2025, 15(14):7127-7153] PubMed: 40585989
HAND1 level controls the specification of multipotent cardiac and extraembryonic progenitors from human pluripotent stem cells [ EMBO J, 2025, 44(9):2541-2565] PubMed: 40164946
An epitranscriptomic program maintains skeletal stem cell quiescence via a METTL3-FEM1B-GLI1 axis [ EMBO J, 2025, 10.1038/s44318-025-00399-z] PubMed: 40016417
Hedgehog signaling activation rescues hypoxia-induced ferroptosis in human brain organoids [ Neural Regen Res, 2025, 10.4103/NRR.NRR-D-25-00338] PubMed: 41017694
Fate plasticity of interneuron specification [ iScience, 2025, 28(4):112295] PubMed: 40264797
Long-term tracking of neural and oligodendroglial development in large-scale human cerebral organoids by noninvasive volumetric imaging [ Sci Rep, 2025, 15(1):2536] PubMed: 39833280
Delayed forebrain excitatory and inhibitory neurogenesis in STRADA-related megalencephaly via mTOR hyperactivity [ bioRxiv, 2025, 2025.05.13.653911] PubMed: 40462897
Robust Production of Parvalbumin Interneurons and Fast-Spiking Neurons from Human Medial Ganglionic Eminence Organoids [ bioRxiv, 2025, 2025.07.01.662594] PubMed: 40631166

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.